191 related articles for article (PubMed ID: 20825649)
1. ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.
Campbell CI; Petrik JJ; Moorehead RA
Mol Cancer; 2010 Sep; 9():235. PubMed ID: 20825649
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel primary mammary tumor cell line reveals that cyclin D1 is regulated by the type I insulin-like growth factor receptor.
Jones RA; Campbell CI; Petrik JJ; Moorehead RA
Mol Cancer Res; 2008 May; 6(5):819-28. PubMed ID: 18505926
[TBL] [Abstract][Full Text] [Related]
3. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.
Dearth RK; Kuiatse I; Wang YF; Liao L; Hilsenbeck SG; Brown PH; Xu J; Lee AV
BMC Cancer; 2011 Aug; 11():377. PubMed ID: 21867536
[TBL] [Abstract][Full Text] [Related]
4. Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors.
Campbell CI; Moorehead RA
BMC Cancer; 2011 Nov; 11():480. PubMed ID: 22070644
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
Lu Y; Zi X; Zhao Y; Pollak M
Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
[TBL] [Abstract][Full Text] [Related]
6. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
Huang X; Gao L; Wang S; McManaman JL; Thor AD; Yang X; Esteva FJ; Liu B
Cancer Res; 2010 Feb; 70(3):1204-14. PubMed ID: 20103628
[TBL] [Abstract][Full Text] [Related]
7. The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis.
Jones RA; Moorehead RA
J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):407-13. PubMed ID: 19002570
[TBL] [Abstract][Full Text] [Related]
8. Reversibility and recurrence of IGF-IR-induced mammary tumors.
Jones RA; Campbell CI; Wood GA; Petrik JJ; Moorehead RA
Oncogene; 2009 May; 28(21):2152-62. PubMed ID: 19377512
[TBL] [Abstract][Full Text] [Related]
9. Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.
Farabaugh SM; Chan BT; Cui X; Dearth RK; Lee AV
Cell Commun Signal; 2016 Oct; 14(1):25. PubMed ID: 27765041
[TBL] [Abstract][Full Text] [Related]
10. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
11. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.
Franks SE; Campbell CI; Barnett EF; Siwicky MD; Livingstone J; Cory S; Moorehead RA
Oncogene; 2012 Jul; 31(27):3298-309. PubMed ID: 22020329
[TBL] [Abstract][Full Text] [Related]
12. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
13. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
14. Inducible expression of dominant negative insulin-like growth factor I receptor in MCF-7 breast cancer cells.
Modha G; Blanchard A; Sidorchuk J; Venditti M; Shiu R; Myal Y
Endocrine; 2003 Dec; 22(3):293-303. PubMed ID: 14709803
[TBL] [Abstract][Full Text] [Related]
15. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
16. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
18. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
19. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells.
Balañá ME; Labriola L; Salatino M; Movsichoff F; Peters G; Charreau EH; Elizalde PV
Oncogene; 2001 Jan; 20(1):34-47. PubMed ID: 11244498
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
Zhao Y; Wang Z; Jiang Y; Yang C
Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
